MedTrace Logo

Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent

NCT03524976 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-10-09

No results posted yet for this study

Summary

The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™ in the embolization of Dural Arteriovenous Fistula

Conditions

  • Dural Arteriovenous Fistula

Interventions

DEVICE

Squid

SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus. This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter.

Sponsors & Collaborators

  • University Hospital Schleswig-Holstein

    collaborator OTHER

  • Dr. Markus Alfred Möhlenbruch

    lead OTHER

Principal Investigators

  • Markus Moehlenbruch, PD Dr. · University Hospital Heidelberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-07-30
Completion
2020-08-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524976 on ClinicalTrials.gov